Commercialization & investment in biotechnology are key forces transforming laboratory discoveries into real-world applications that benefit health, industry, and the environment. This domain bridges the gap between research innovation and market readiness, involving intellectual property strategies, regulatory navigation, and business model development. Investors, venture capitalists, and corporate partners play a crucial role in funding early-stage biotech startups, clinical trials, and manufacturing scale-up. Commercialization & Investment in Biotechnology also include public-private partnerships and technology transfer offices that support licensing and entrepreneurship. As competition intensifies, strategic alliances and investor confidence hinge on strong scientific validation, scalable platforms, and clear regulatory pathways. This process not only accelerates product development but ensures that scientific breakthroughs reach patients, consumers, and industries worldwide.
Title : Renewed novel biotech ideas, with bioreactor bioengineering economic impact
Murray Moo Young, University of Waterloo, Canada
Title : Osmotic lysis–driven Extracellular Vesicle (EV) engineering
Limongi Tania, University of Turin, Italy
Title : Steps and strides: Cross-species insights into movement and injury
Babak Faramarzi, Western University of Health Sciences, United States
Title : Eliminating implant failure in humans with nano chemistry: 45,000 cases and counting
Thomas J Webster, Brown University, United States
Title : Scientist’s computational lawyer
Julia Sidorova, Instituto Carlos III de Salud (CIBER-EHD), Spain
Title : Evaluating cell compatibility and subcutaneous host response of silk fibroin–chitosan plug composites as potential resorbable implants
Luis Jesus Villarreal Gomez, Universidad Autonoma de Baja California, Mexico